他达拉非每日给药治疗男性勃起功能障碍:一项对包括1913患者的6个随机双盲安慰剂对照试验的整合分析

Tadalafil Once Daily in Men with Erectile Dysfunction: An Integrated Analysis of Data Obtained from 1913 Patients from Six Randomized, Double-blind, Placebo-controlled, Clinical Studies
2013-10-23 01:27点击:1127次发表评论
期刊: EUR UROL2013年10月期卷

Background
This analysis explores tadalafil once-daily treatment for 12 wk in clinical subpopulations of men with erectile dysfunction (ED).

Objective
Assess the efficacy and safety of once-daily tadalafil mg 2.5 and mg 5 in patients with different ED characteristics and comorbidities.

Design, setting, and participants
This analysis integrated data from six randomized, double-blind, placebo-controlled studies that assigned 1913 men with ≥3-mo history of ED either to once-daily placebo 596), = (n tadalafil mg 2.5 394), = (n or tadalafil mg 5 923). = (n Clinical factors examined included: ethnicity, age, obesity, alcohol consumption, smoking, comorbidities, concomitant medication, and ED characteristics (etiology, duration, severity).

Outcome measurements and statistical analysis
Descriptive statistics were reported for efficacy and safety, including International Index of Erectile Function Erectile Function Domain (IIEF-EF) scores and Sexual Encounter Profile question 3 (SEP3) responses. Clinical factors were included in analysis of covariance models using last observation carried forward for SEP3 and IIEF-EF scores.

Results and limitations
Both tadalafil doses significantly improved SEP3 responses (least-squares [LS] mean change: 17.8% and 23.6%, respectively) and IIEF-EF scores (LS mean change: 4.2; 5.4) compared with placebo  (p<0.01).  Treatment with mg 2.5 and mg 5 tadalafil resulted in IIEF-EF LS mean improvements ≥4 (minimal clinically important difference [MCID]) in patients with hypertension (4.3 [95% confidence interval (CI), 2.9–5.7]; 4.7 [95% CI, 3.5–5.8]), cardiac disorder (7.0 [95% CI, 4.7–9.3]; 6.3 [95% CI, 4.4–8.2]), or hyperlipidemia (5.3 [95% CI, 3.4–7.1]; 5.8 [95% CI, 4.3–7.4]). Obese patients (4.7 [95% CI, 3.4–6.0]), smokers (4.8 [95% CI, 3.0–6.7]), and psychogenic ED (7.3 [95% CI, 5.0–9.6]) reached MCID only after treatment with mg 5 tadalafil. Severity-specific MCID (IIEF-EF change ≥7) was achieved by 44.5% of patients with severe baseline ED treated with tadalafil mg, 5 compared with 11.6% of placebo-treated patients. No unexpected safety findings were observed. These analyses were performed on integrated data and can only provide descriptive results to guide further investigations.

Conclusions
Treatment with tadalafil mg 2.5 or mg 5 once daily was well tolerated and resulted in clinically important improvements in patients with mild (54.3% and 74.8%, respectively), moderate (51.3% and 63.1%, respectively), or severe (33.7% and 44.5%, respectively) ED.

 

学科代码:泌尿外科学   关键词:Tadalafil;Erectile Dysfunction ,全球精选文摘 爱思唯尔医学网, Elseviermed
顶一下(0
您可能感兴趣的文章
    发表评论网友评论(0)
      发表评论
      登录后方可发表评论,点击此处登录